Angiogenetic Factors in Chronic Subdural Hematoma Development

Area of Science:

• Neuroscience
• Vascular Biology
• Biochemistry

Background:

• Chronic subdural hematoma (CSH) is a common neurosurgical condition, often treated with surgical evacuation or, more recently, embolization.
• Recurrence and rebleeding are significant challenges in CSH management, necessitating a deeper understanding of underlying pathomechanisms.
• Angiogenesis, the formation of new blood vessels, plays a critical role in various pathological processes, including hematoma evolution and recurrence.

Observation:

• This study investigated the levels of key angiogenic factors—vascular endothelial growth factor (VEGF), matrix metallopeptidase 9 (MMP-9), angiopoietin-2 (Ang2), transforming growth factor-beta 1 (TGF-β1), and platelet-derived growth factor-BB (PDGF-BB)—in patients undergoing embolization for CSH.
• Analysis focused on peripheral venous blood samples, revealing distinct patterns in angiogenic factor profiles.
• Patients with CSH exhibited an imbalance in angiogenic factors, characterized by decreased levels of factors promoting vessel wall growth (TGF-β1, PDGF-BB) and elevated levels of factors involved in extracellular matrix degradation (MMP-9).

Findings:

• Vascular endothelial growth factor (VEGF) levels were generally normal or slightly decreased in CSH patients.
• Matrix metallopeptidase 9 (MMP-9) levels were significantly elevated in all patients, indicating increased vessel wall degradation.
• Angiopoietin-2 (Ang2) and particularly transforming growth factor-beta 1 (TGF-β1) and platelet-derived growth factor-BB (PDGF-BB) levels were notably low in most cases, with slight elevations only in previously operated patients.

Implications:

• The observed imbalance in angiogenic factors suggests a pro-hemorrhagic state in recurrent or rebleeding CSH.
• This angiogenic profile, with reduced vessel repair factors and increased degradation factors, may serve as a biomarker for predicting hemorrhage risk in CSH patients.
• Understanding these molecular mechanisms could pave the way for novel therapeutic strategies targeting angiogenesis to prevent CSH recurrence and rebleeding.